scholarly journals Functional mechanism of ASP5736, a selective serotonin 5-HT5A receptor antagonist with potential utility for the treatment of cognitive dysfunction in schizophrenia

2018 ◽  
Vol 28 (5) ◽  
pp. 620-629 ◽  
Author(s):  
Mayako Yamazaki ◽  
Noriyuki Yamamoto ◽  
Junko Yarimizu ◽  
Mayuko Okabe ◽  
Ai Moriyama ◽  
...  
2009 ◽  
Vol 5 (4S_Part_8) ◽  
pp. P245-P245
Author(s):  
Jay S. Schneider ◽  
Emmanuel Decamp ◽  
Michael Hill ◽  
Erwan Bezard ◽  
Alan Crossman ◽  
...  

2014 ◽  
Vol 731 ◽  
pp. 88-92 ◽  
Author(s):  
Mari Nakata-Fukuda ◽  
Takuya Hirata ◽  
Yoshihiro Keto ◽  
Mayumi Yamano ◽  
Toshihide Yokoyama ◽  
...  

2014 ◽  
Vol 27 (1) ◽  
pp. 53-55 ◽  
Author(s):  
Abhishek Reddy ◽  
Sowmya C Puvvada ◽  
Satyanarayana Kommisetti ◽  
Rif S. El-Mallakh ◽  
Steven Lippmann

Orexin, also called hypocretin, is a neuropeptide that acts on central nervous system receptors to promote arousal. Suvorexant, its receptor antagonist, generates interest as a medication to treat insomnia. Suvorexant helps in decreasing wakefulness by counteracting orexin activity. Its low side effect potential may offer considerable benefit. Compared with other sleep aids, diminished drowsiness and less cognitive dysfunction is an advantage. Now approved for clinical use, an apparent lack of rebound insomnia or drug dependence potential might make suvorexant a good choice pharmacotherapy for patients with insomnia.


1991 ◽  
Vol 57 (3) ◽  
pp. 387-395
Author(s):  
Takeshi Kamato ◽  
Keiji Miyata ◽  
Hiroyuki Ito ◽  
Hidenobu Yuki ◽  
Mayumi Yamano ◽  
...  

2019 ◽  
Vol 29 ◽  
pp. S414-S415
Author(s):  
T.H. Svensson ◽  
M. Yamazaki ◽  
N. Yamamoto ◽  
J. Yarimizu ◽  
M. Okabe ◽  
...  

2013 ◽  
Vol 25 (2) ◽  
pp. 77-84 ◽  
Author(s):  
Takahiro Masuda ◽  
Hiroyuki Nishikawa ◽  
Takeshi Inoue ◽  
Hiroyuki Toda ◽  
Shin Nakagawa ◽  
...  

ObjectiveSelective serotonin reuptake inhibitors (SSRIs) have been widely used in the treatment of most anxiety disorders. In this study, to clarify the mechanism of the anxiolytic effect, we investigated the mechanism underlying the effect of the SSRI citalopram on rat contextual conditioned fear stress (CFS), an animal model of anxiety.MethodsRats individually received footshocks in a shock chamber. More than 1 day later, they were given citalopram and/or dl‐p‐chlorophenylalanine (PCPA), various subtype‐selective serotonin (5‐HT) receptor antagonists: the 5‐HT1A receptor antagonist WAY 100635, the 5‐HT2A receptor antagonist MDL 100907, the 5‐HT2C receptor antagonist SB 242084, the 5‐HT3 receptor antagonist tropisetron, the 5‐HT4 receptor antagonist GR 125487, the 5‐HT6 receptor antagonist SB 258585 or the 5‐HT7 receptor antagonist SB 269970. After drug administration, freezing behaviour, which was used as an index of anxiety, was analysed in the same shock chamber without shocks.ResultsCitalopram dose dependently reduced conditioned freezing behaviour. The anxiolytic‐like effect of citalopram was prevented completely by pretreatment with the 5‐HT‐depleting agent PCPA, but not by the 5‐HT1A receptor antagonist WAY 100635. Furthermore, none of the subtype‐selective 5‐HT receptor antagonists significantly affected conditioned freezing or affected the anxiolytic‐like effect of citalopram.ConclusionThe anxiolytic‐like effect of citalopram in contextual CFS model depends on 5‐HT availability. In addition, contextual CFS model is suggested to be completely different from conventional anxiety models in neural mechanism or manners of serotonergic involvement. However, further studies are needed to identify the pharmacological mechanisms responsible for the anxiolytic‐like effect of citalopram.


Sign in / Sign up

Export Citation Format

Share Document